Arcutis Biotherapeutics (NASDAQ:ARQT) Price Target Increased to $18.00 by Analysts at Mizuho

Arcutis Biotherapeutics (NASDAQ:ARQT – Free Report) had its target price raised by Mizuho from $17.00 to $18.00 in a report released on Wednesday morning, Benzinga reports. They currently have a buy rating on the stock. Several other research firms also recently commented on ARQT. Needham & Company LLC reiterated a buy rating and issued a […]

Related Keywords

Los Angeles ,California ,United States ,China ,Dekabank Deutsche Girozentrale ,Masaru Matsuda ,Arcutis Biotherapeutics ,China Universal Asset Management Co ,Arcutis Biotherapeutics Inc ,Los Angeles Capital Management ,Securities Exchange Commission ,Needham Company ,Nasdaq ,Arcutis Biotherapeutics Company Profile ,Goldman Sachs Group ,Free Report ,Moderate Buy ,Get Free Report ,Exchange Commission ,Bank Deutsche Girozentrale ,Angeles Capital Management ,Universal Asset Management ,Trexquant Investment ,